Literature DB >> 24703520

The effects of emphysema on airway disease: correlations between multi-detector CT and pulmonary function tests in smokers.

Misuzu Yahaba1, Naoko Kawata2, Ken Iesato3, Yukiko Matsuura4, Toshihiko Sugiura5, Hajime Kasai6, Yoriko Sakurai7, Jiro Terada8, Seiichiro Sakao9, Yuji Tada10, Nobuhiro Tanabe11, Koichiro Tatsumi12.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation caused by emphysema and small airway narrowing. Quantitative evaluation of airway dimensions by multi-detector computed tomography (MDCT) has revealed a correlation between airway dimension and airflow limitation. However, the effect of emphysema on this correlation is unclear.
OBJECTIVE: The goal of this study was to determine whether emphysematous changes alter the relationships between airflow limitation and airway dimensions as measured by inspiratory and expiratory MDCT.
METHODS: Ninety-one subjects underwent inspiratory and expiratory MDCT. Images were evaluated for mean airway luminal area (Ai), wall area percentage (WA%) from the third to the fifth generation of three bronchi (B1, B5, B8) in the right lung, and low attenuation volume percent (LAV%). Correlations between each airway index and airflow limitation were determined for each patient and compared between patients with and without evidence of emphysema.
RESULTS: In patients without emphysema, Ai and WA% from both the inspiratory and expiratory scans were significantly correlated with FEV1. No correlation was detected in patients with emphysema. In addition, emphysematous COPD patients with GOLD stage 1 or 2 disease had significantly lower changes in B8 Ai than non-emphysematous patients.
CONCLUSIONS: A significant correlation exists between airway parameters and FEV1 in patients without emphysema. Emphysema may influence airway dimensions even in patients with mild to moderate COPD.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Airway luminal area; Chronic obstructive pulmonary disease; Low attenuation volume percentage; Multi-detector computed tomography; Wall area percentage

Mesh:

Year:  2014        PMID: 24703520     DOI: 10.1016/j.ejrad.2014.03.003

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Authors:  Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

2.  Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome.

Authors:  Toshio Suzuki; Yuji Tada; Naoko Kawata; Yukiko Matsuura; Jun Ikari; Yasunori Kasahara; Koichiro Tatsumi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-05-15

3.  Time-series hyperpolarized xenon-129 MRI of lobar lung ventilation of COPD in comparison to V/Q-SPECT/CT and CT.

Authors:  Ozkan Doganay; Tahreema Matin; Mitchell Chen; Minsuok Kim; Anthony McIntyre; Daniel R McGowan; Kevin M Bradley; Thomas Povey; Fergus V Gleeson
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

4.  Influence of pulmonary emphysema on COPD assessment test-oriented categorization in GOLD document.

Authors:  Toshio Suzuki; Yuji Tada; Naoko Kawata; Jun Ikari; Yasunori Kasahara; Yoriko Sakurai; Ken Iesato; Rintaro Nishimura; James West; Koichiro Tatsumi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-19

5.  Quantitative computed tomography phenotypes, spirometric parameters, and episodes of exacerbation in heavy smokers: An analysis from South America.

Authors:  Marcelo Cardoso Barros; Bruno Hochhegger; Stephan Altmayer; Guilherme Watte; Matheus Zanon; Ana Paula Sartori; Daniela Cavalet Blanco; Gabriel Sartori Pacini; Jose Miguel Chatkin
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.